Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Evidence on Patients With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Long-term Survival After Treatment With Liposomal Irinotecan (NALLONG)

NCT06155136 is registered in ClinicalTrials.gov with Servier Affaires Médicales as lead sponsor.

NCT NCT06155136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06155136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Evidence on Patients With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Long-term Survival After Treatment With Liposomal Irinotecan (NALLONG)
Lead sponsor
Servier Affaires Médicales
Phase
Observational
Overall status
Unknown status
Start date
October 6, 2023
Completion date
September 30, 2024
Enrollment
163 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer metastatic